Biopharmaceutical innovation is rapidly advancing, with contract research, development, and manufacturing organizations (CRDMOs) playing a crucial role in facilitating the transition from scientific discoveries to market-ready therapies. Nick Challoner, CEO of Ingenza, emphasizes the importance of understanding customer needs and accelerating development timelines to remain competitive. He highlights Ingenza’s dual-engineering biotechnology approach, integrating AI with expert knowledge, as key to meeting these demands. With a focus on protein development, Ingenza aims to position itself as a leading CRDMO in human and animal health and sustainable technologies, targeting substantial growth in the lucrative protein therapeutics market by 2030.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.contractpharma.com/the-future-of-biotech-outsourcing/
